Heather Hebert
Acute Care · Shreveport, LANPI 1093825382
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Phathom Pharmaceuticals, Inc. at 56.7% of the total. 2025 is the largest year on record at $5,480, more than ten times the $343 reported in 2021. Among acute care clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 220 payments — averaging $39.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$5K
- AbbVie$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$596
- Sanofi$420
- Takeda Pharmaceuticals U.S.A., Inc.$264
- Ardelyx, Inc.$217
- plus $888 from 14 others
What the payments were for
- Speaking & faculty fees$4,10047%
- Travel & lodging$3654%
- Food & beverage$4,11447%
- Education$841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 25 | $4,914 |
| AbbVie | 77 | $1,364 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 45 | $596 |
| Sanofi | 18 | $420 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $264 |
| Ardelyx, Inc. | 5 | $217 |
| Evoke Pharma, Inc. | 4 | $208 |
| Johnson & Johnson | 6 | $179 |
| Bristol Myers Squibb | 9 | $156 |
| Incyte Corporation | 1 | $125 |
| Lilly USA, LLC | 3 | $54 |
| Daiichi Sankyo Inc. | 2 | $38 |
| QOL Medical, LLC | 1 | $22 |
| Redhill Biopharma Inc. | 1 | $18 |
| Madrigal Pharmaceuticals | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| Vivus LLC | 1 | $15 |
| Braintree Laboratories, Inc. | 1 | $14 |
| Axonics, Inc. | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,663 in reported general payments places this provider in the 95th percentile of 248 acute care providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 21 | $565,213 |
| RinvoqUpadacitinib | 13 | $110,084 |
| LinzessLinaclotide | 95 | $64,933 |
| Mesalamine | 54 | $10,063 |
| TrulancePlecanatide | 14 | $9,783 |
| MotegrityPrucalopride Succinate | 12 | $7,211 |
| Mesalamine ErMesalamine | 14 | $6,317 |
| Colestipol Hcl | 39 | $5,092 |
| Omeprazole | 252 | $3,595 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 157 | $3,536 |
| Sucralfate | 49 | $3,343 |
| Pantoprazole Sodium | 233 | $3,248 |
| Budesonide DrBudesonide | 36 | $2,801 |
| Lansoprazole | 39 | $1,148 |
| Baclofen | 54 | $827 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $179 | $565,21321 claims |
| AbbVieRinvoq, Linzess | $1,364 | $175,017108 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $596 | $9,78314 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $264 | $7,21112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 248 acute care providers in Louisiana.
Other acute care in Shreveport
- Brinton FegleyShreveport$61K
- Jeremy DavisShreveport$35K
- Heather MecomShreveport$17K
- Mary HireShreveport$11K
- Sammi SmithShreveport$10K
- Richard ChoateShreveport$7K
- Jennifer NinhShreveport$6K
- Laurie SimmonsShreveport$5K
- Brandy RambinShreveport$5K
- April ChaseShreveport$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.